Use of a regional registry of chronic hepatitis patients to optimize antiviral therapy

Tkachenko L.I.; Maleev V.V.; Sannikova I.V.; Titorenko M.V.

doi:https://doi.org/10.17116/terarkh201587858-66

Tkachenko L.I.

Stavropol State Medical University, Ministry of Health of the Russia, Stavropol, Russia

Maleev V.V.

FBUN «Tsentral'nyj nauchno-issledovatel'skij institut epidemiologii» Rospotrebnadzora, Moskva

Sannikova I.V.

Stavropol State Medical University, Ministry of Health of Russia, Stavropol, Russia

Titorenko M.V.

Stavropol State Medical University, Ministry of Health of Russia, Stavropol, Russia

Use of a regional registry of chronic hepatitis patients to optimize antiviral therapy

Authors:

Tkachenko L.I., Maleev V.V., Sannikova I.V., Titorenko M.V.

More about the authors

Journal: Therapeutic Archive. 2015;87(8): 58‑66

DOI: 10.17116/terarkh201587858-66

Read: 2781 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Tkachenko LI, Maleev VV, Sannikova IV, Titorenko MV. Use of a regional registry of chronic hepatitis patients to optimize antiviral therapy. Therapeutic Archive. 2015;87(8):58‑66. (In Russ.)
https://doi.org/10.17116/terarkh201587858-66

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Long-term outcomes in patients after hospital treatment for COVID-19 (three-year follow-up data). Russian Journal of Preventive Medicine. 2024;(12):114-121

Features of drug therapy in patients with chronic heart failure in real clinical practice (chronic heart failure registry in the Tyumen region). Russian Cardiology Bulletin. 2024;(4):72-79

Prevalence and role of elevated serum lipoprotein(a) in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Russian Cardiology Bulletin. 2025;(1):39-48

Abstract:

Aim. To determine the general characteristics of patients with chronic viral hepatitis C (CVHC) from the data of a registry of patients with viral hepatitis (VH) in the Stavropol Territory and to estimate possible predictors for the inefficiency of antiviral therapy (AVT) for treatment optimization. Subjects and methods. The results of examining and treating patients with CVHC were retrospectively analyzed from the data of the registry of HV patients in the Stavropol Territory in 2008—2013. Results. The chronic hepatitis registry includes 1811 patients with CVHC; out of them there are 64% who have its virus genotype 1. According to the registry, there is cirrhosis in 244 (13.5%) patients, fibrosis (METAVIR F2-F3 in 724 (39.97%), and fibrosis (METAVIR F0-F1) in the remaining 843. Carbohydrate and fat metabolic disturbances (obesity, insulin resistance (IR), and diabetes mellitus (DM)) have been found in 615 (34%) patients; every three patients have gastrointestinal diseases and comorbidity is absent in 24% of the patients. The results of AVT were analyzed in 493 patients with CHC virus genotype 1. The analysis showed the most important predictors for the inefficiency of AVT; these included HOMA-IR >2, the presence of IR (HOMA-IR >2.77), and type 2 DM, as well as patient age over 45 years, male sex, a viral load of ≥6 log10 IU/ml, and liver fibrosis (METAVIR ≥F3). Conclusion. The analysis of VH morbidity in the Stavropol Territory, the making of a registry of patients with chronic VH, its columns of IR, body mass index, virologic response changes during therapy could clarify the actual need in AVT and improve activities in the prophylactic medical examination and treatment optimization in this patient group in the areas of this region.

Keywords:

general characteristics of patients with chronic hepatitis C; registry; predictors for inefficiency of therapy

Authors:

Tkachenko L.I.

Stavropol State Medical University, Ministry of Health of the Russia, Stavropol, Russia

Maleev V.V.

FBUN «Tsentral'nyj nauchno-issledovatel'skij institut epidemiologii» Rospotrebnadzora, Moskva

Sannikova I.V.

Stavropol State Medical University, Ministry of Health of Russia, Stavropol, Russia

Titorenko M.V.

Stavropol State Medical University, Ministry of Health of Russia, Stavropol, Russia

Close metadata

References:

Yushchuk N.D., Znoiko O.O., Yakushechkina N.A., Dudina K.R., Shut'ko S.A., Kozina A.N., Safiullina N.Kh., Fedoseeva N.V., Belyi P.A., Lugovskikh E.A., Rakhmanova A.G., Khubutiya M.Sh., Pimenov N.N., Chulanov V.P., Chesnokov E.V., Ogarev V.V. Otsenka sotsial'no-ekonomicheskogo bremeni gepatita S v Rossiiskoi Federatsii. Epidemiologiya i vaktsinoprofilaktika. 2013;2(69):13-33.
Pimenov N.N., Vdovin A.V., Komarova S.V. Mamonova N.A., Chulanov V.P., Pokrovskii V.I. Aktual'nost' i perspektivy vnedreniya v Rossii edinogo federal'nogo registra bol'nykh virusnymi gepatitami V i S. Terapevticheskii arkhiv. 2013;11:4-9.
Christensen PB, Hay G, Jepsen P, Omland LH, Just SA, Krarup HB, Weis N, Obel N, Cowan S. Hepatitis C prevalence in Denmark — an estimate based on multiple national registers. BMC Infectious Diseases. 2012;12:178-185.
Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, De Angelis D. Hepatitis C infection among injecting drug users in England and Wales (1992—2006): there and back again? Am J Epidemiol. 2009;170:352-360.
O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2013 godu: Gosudarstvennyi doklad. M.: Federal'naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka; 2014;191.
Gosudarstvennyi doklad «O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Stavropol'skom krae v 2013 godu». 2014;152.
Glants S. Mediko-biologicheskaya statistika. Per s angl. M.: Praktika; 1998;459.
Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus . Gastroenterology. 2010;139(1):120-129.
Khafisova O.O., Polikarpova T.S., Mazurchik N.V., Ogurtsov P.P. Vliyanie metformina na formirovanie ustoichivogo virusologicheskogo otveta pri provedenii kombinirovannoi protivovirusnoi terapii khronicheskogo gepatita S PegIFNα-2b i ribavirinom. Vestnik RUDN. 2011;2:47-55.
Pis'mo ministra zdravookhraneniya RF №24—0/10/2—4915 ot 10 dekabrya 2012 goda.
Yushchuk N.D., Safiullina N.Kh., Yur'eva A.E. Znoiko O.O., Dudina K.R., Lenkova D.O., Malyshev N.A., Myasnikov V.A., Belyi P.A., Kelli E.I. Analiz profilya bol'nykh virusnym gepatitom S, postupavshikh v infektsionnye statsionary g. Moskvy v 2010 godu. Lechashchii vrach. 2014;1:63-67.
Mason AL, Lau JYN, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, Everhart JE, Wasserfall C, Maclaren NK, Perrillo RP. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328-33.
Mehta SH, Brancati FL, Sulkowsky MS, Strathdee SA, Szklo M, Thomas DL. Prevalence type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592-599.
Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75:355-359.
Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. AnnIntern Med. 2004;140(5):346-355.
Van Vlierberghe H, Adler M, Bastens B, Colle I, Delwaide J, Henrion J, Horsmans Y, Michielsen P, Golstein P, Mulkay JP, Van Steenbergen W, Yap P, Nevens F, Denys AM, Brasseur JP. Effectiveness and tolerability of pegylated interferon alfa-2b in combination with ribavirin for treatment of chronic hepatitis C: the PegIntrust Study. Acta Gastro-EnterologicaBelgica. 2010;LXXIII:5-11.
Bondini S, Younossi ZM. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Gastroenterol Dietol. 2006;52(2):135-143.
Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75-85.
Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, Paradis V, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134:416-423.
Antonova T.V., Romanova M.A., Sergeeva E.G. Khronicheskii gepatit S u bol'nykh s metabolicheskim sindromom. Zhurnal infektologii. 2011;3(3):91-96.
Baizhanova Zh.Zh., Ignatova T.M., Severova M.M., Burnevich E.Z. Steatoz pecheni i insulinorezistentnost' pri khronicheskom gepatite S. Farmateka. 2012;7:26-29.
Nikitin I.G., Bogomolov P.O. Insulinorezistentnost' i gepatit S: mogut li nashi predstavleniya izmenit' podkhody k lecheniyu? Farmateka. Gastroenterologiya, gepatologiya. 2007;2:15-19.